Claudia Zylberberg
Board Chair and Co-Founder, Kosten Digital; Board Chair and Co-Founder, Arscience Biotherapeutics; Foundation Board Member, Alliance for mRNA Medicines
First appearing in our Power List in 2019, Claudia continues to innovate across the cell and gene therapy space, and throughout biopharma more broadly. Her latest endeavor is co-founding and launching Kosten Digital to leverage AI technologies that can optimize cell and gene therapy development and manufacturing. Other roles include CEO at Akron Bio, board member of Canada’s Centre for Commercialization of Regenerative Medicine, Alliance of Regenerative Medicine (ARM) and the ARM Foundation, International Society for Cell & Gene Therapy, Standards Coordinating Body, Octomera, and Arscience Biotherapeutics (which she also co-founded).
“My career started in human plasma, but science has a way of guiding you forward. Following that path led me to cell and gene therapy — a field with the power not only to treat disease, but to fundamentally correct or even cure it at the source. What inspired me most was the once-in-a-lifetime opportunity to help build this industry from the ground up — to be there at the start, to dream big, and then to put in the hard work required to turn those dreams into reality. The chance to help reshape the very fabric of medicine was — and still is — irresistible.”
